Australia's NeuroScientific jumps on positive prelim drug trial data

Neuroscientific Biopharmaceuticals

15/06/2022 02:14

** Shares of NeuroScientific Biopharmaceuticals  NSB.AX 
climb as much as 22.9% to A$0.215, set to mark their best day
since May 21, 2021, if gains hold
    ** Drugmaker for neuro-related conditions reports positive
preliminary results for its drug candidate, EmtinB, from an
animal study for multiple sclerosis  urn:newsml:reuters.com:*:nASX1hY2V1
    ** Stock hits highest since June 9
    ** Co says results showed a reduction in the severity of the
disease, from the onset of symptoms and through to the peak,
when compared to untreated controls
    ** Says it will progress EmtinB into a larger study, and
expects to report a full set of results in the second half of
2022
    ** Stock down 47.8% YTD, as of last close 

 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))